- Preclinical safety assessment of recombinant botulinum vaccine A/B (rBV A/B)Jeffry D Shearer
DynPort Vaccine Company LLC, A CSC Company, Frederick, MD 21702, USA
Vaccine 30:1917-26. 2012..Together these results indicated a favorable safety profile for rBV A/B and supported its use in a Phase 1 clinical trial...
- Biological activity of an intravenous preparation of human vaccinia immune globulin in mouse models of vaccinia virus infectionJeffry D Shearer
DVC LLC, 64 Thomas Johnson Drive, Frederick, Maryland 21702, USA
Antimicrob Agents Chemother 49:2634-41. 2005..The timing of treatment relative to VV inoculation appeared to be important for the demonstration of VIGIV's biological activity...
- Botulinum neurotoxin neutralizing activity of immune globulin (IG) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rBV A/B)Jeffry D Shearer
DynPort Vaccine Company LLC, A CSC Company, 64 Thomas Johnson Drive, Frederick, MD 21702, USA
Vaccine 28:7313-8. 2010..Additionally, estimates of the neutralizing efficiency have been established for BoNT/A1 and BoNT/B1 neutralizing antibodies obtained from clinical volunteers vaccinated with the rBV A/B...